Table 3 Changes in parameters in type 2 diabetic patients (n = 36)
From: Does glycemic control reverse dispersion of ventricular repolarization in type 2 diabetes?
| Â | Baseline | Follow-up | P |
|---|---|---|---|
Clinical variables | Â | Â | Â |
Duration of treatments (days) | - | 787.0 ± 300.8 |  |
BMI (kg/m2) | 26.5 ± 4.7 | 26.0 ± 4.8 | 0.239 |
SBP (mmHg) | 126.6 ± 18.0 | 127.5 ± 14.9 | 0.564 |
DBP (mmHg) | 75.1 ± 9.9 | 71.0 ± 9.4 | 0.051 |
Laboratory variables | Â | Â | Â |
HbA1c (%) | 10.0 ± 1.7 | 7.3 ± 1.6 | <0.001 |
Triglyceride (mg/dl) | 184.8 ± 120.2 | 148.5 ± 81.9 | 0.043 |
HDL-C (mg/dl) | 44.4 ± 11.8 | 46.9 ± 13.1 | 0.289 |
LDL-C (mg/dl) | 116.0 ± 41.5 | 97.3 ± 28.8 | 0.020 |
Creatinine (mg/dl) | 0.67 ± 0.23 | 0.99 ± 0.85 | 0.011 |
Uric acid (mg/dl) | 4.9 ± 1.2 | 5.1 ± 1.4 | 0.504 |
Potassium (mEq/l) | 4.2 ± 0.4 | 4.1 ± 0.5 | 0.734 |
Medications | Â | Â | Â |
ACE-I/ARB | 13 (36.1%) | 18 (50.0%) | 0.341 |
CCB | 11 (30.6%) | 12 (33.3%) | 1.000 |
β blocker | 5 (13.9%) | 6 (16.7%) | 1.000 |
Other antihypertensive drugs | 6 (16.7%) | 8 (22.2%) | 0.767 |
Sulphonylurea | 17 (47.2%) | 13 (36.1%) | 0.474 |
α-glucosidase inhibitor | 16 (44.4%) | 11 (30.6%) | 0.330 |
Biguanide | 14 (38.9%) | 18 (50.0%) | 0.477 |
DPP-4 inhibitor | 10 (27.8%) | 27 (75.0%) | <0.001 |
Insulin | 7 (19.4%) | 10 (27.8%) | 0.580 |
Other antidiabetic drugs | 4 (11.1%) | 2 (5.6%) | 0.674 |
Statin | 12 (33.3%) | 18 (50.0%) | 0.232 |
Fibrate | 2 (5.6%) | 1 (2.8%) | 1.000 |
Electrocardiographic variables | Â | Â | Â |
Heart rate (bpm) | 73.6 ± 14.4 | 70.6 ± 11.0 | 0.156 |
V1S + V5R (mV) | 2.42 ± 0.60 | 2.58 ± 0.74 | 0.097 |
QTc mean (ms) | 414.1 ± 19.3 | 414.8 ± 23.0 | 0.843 |
QT dispersion (ms) | 41.4 ± 16.6 | 45.8 ± 15.0 | 0.165 |
QTc dispersion (ms) | 45.1 ± 16.8 | 46.8 ± 14.4 | 0.564 |
Tpeak-Tend in V5 (ms) | 85.0 ± 12.9 | 83.6 ± 10.6 | 0.563 |